Biotech | August 09, 2021
AstraZeneca Pharma India PAT at Rs 10.24 crores
Board declares interim dividend of Rs 2 per equity share
Board declares interim dividend of Rs 2 per equity share
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
Board approves fundraise of Rs 1500 crore
Forex gains stood at Rs 20 crore for the quarter
India business contributes to a stellar performance
Aditya Puri former MD of HDFC bank joins Solara board as chairman
Nureca Ltd has reported financial results for the period ended June 30, 2021.
The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Subscribe To Our Newsletter & Stay Updated
